Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening
Wei Zhu(Guangzhou University of Chinese Medicine), Wei Zheng(Liaoning Cancer Hospital & Institute), Sam Michael(National Institutes of Health), Min Shen(Kaili University), Miao Xu(Shandong University), Xin Hu(Discovery Institute), Hui Guo(First Affiliated Hospital of Xi'an Jiaotong University), Catherine Z. Chen(National Institutes of Health), Paul Shinn(National Institutes of Health), Carleen Klumpp‐Thomas(National Institutes of Health)
Cited by 27
Related Papers
Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus
|Nature Medicine|2016|570
Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium
|Cell stem cell|2020|460
Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia
|Cancer Cell|2015|348
Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening
|Science Translational Medicine|2019|259
Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs
|Emerging Microbes & Infections|2014|242